Altered clot kinetics in patients with non-alcoholic fatty liver disease
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 4
Abstract
Background. Emerging evidence has linked the presence of non-alcoholic fatty liver disease (NAFLD) with an increased risk for cardiovascular events. We hypothesised that altered clot kinetics and platelet function may contribute to this increased risk. This study compared whole blood clotting kinetics in patients with 1) non-cirrhotic NAFLD (n = 28) and 2) healthy control subjects (n = 22). Methods. Clotting kinetics were assessed in whole blood using thromboelastography (TEG) and assessed for correlations with cardiovascular risk factors. Results. Clot kinetics in patients with NAFLD showed significantly stronger clot development (maximum amplitude (MA); 58.3 ± 6.3 mm vs. 52.0 ± 10.1 mm, p = 0.01) and reduced clot lysis in the presence of thrombin (35 ± 30% vs. 51 ± 26% clot lysis 30 minutes after MA, p = 0.03) compared to control subjects. Clot strength was independently positively associated with body mass index in NAFLD, but not in control subjects. There was a greater platelet contribution to clot strength in patients with NAFLD compared to controls despite similar platelet counts. There was no association between clot kinetics and features of the metabolic syndrome or presence of type 2 diabetes. Conclusion. Patients with NAFLD have disturbances in ex-vivo clot kinetics including increased clot strength and clots that are more resistant to thrombin-stimulated lysis.
Authors and Affiliations
Ingrid Hickman, Clair Sullivan, Simone Flight, Catherine Campbell, Darrell Crawford, Paul Masci, Trisha O’Moore-Sullivan, Johannes Prins, Graeme Macdonald
Keywords
Related Articles
- EP ID EP77888
- DOI -
- Views 113
- Downloads 0
Aspartate aminotransferase-to-platelet ratio index (APRI) for the non-invasive prediction of esophageal varices
Background & Aims. Variceal bleeding is a dramatic and common complication of cirrhosis, and, therefore, endoscopy is recommended for the screening of EV (esophageal varices) in every cirrhotic. This study ev...
Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant
Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclata...
Inter and intrapatient evolution of hepatitis C virus
Hepatitis C virus (HCV) has a short replication time, high mutation rates and large population sizes, all of which make it an excellent experimental model for evolution studies, because evolution can be visualized in rea...
Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis B infection in hemodialysis patients: a nationwide study
[b]Background[/b]. Recent studies have demonstrated that prevention of hepatitis B virus (HBV) transmission remains a challenge in hemodialysis (HD) patients. The aim of this study is to explore factors which increase th...
Adult living donor versus deceased donor liver transplantation: A 10- year prospective single center experience
It has been 4 years since the first, long-term (> 3 years) prospective comparison of adult-to-adult living donor liver transplantation (A2ALLTx) to adult deceased donor liver transplantation (ADDLTx) was repor...